Strain matters more than CFU count, and most probiotic marketing leads with the wrong number. Independent testing has found real gaps between label claims and what’s actually in the capsule. What’s worth checking before buying: the exact strain name, the dose used in trials, and whether the company discloses testing at all.
You probably already have a probiotic in the cabinet. Maybe two. The kind with a number in the billions across the front and a blend of species you couldn’t pronounce if someone asked, taken most mornings for a couple of months now, with no real way to tell whether it’s doing anything.
That’s not a discipline problem. It’s a design problem with how these products are sold. “50 billion CFU” in size-forty font tells you almost nothing about whether that specific product will help the specific pattern you’re dealing with, and the industry has generally been comfortable with that gap, because a bigger number is an easy thing to print and a hard thing to argue with at the shelf.
The estrobolome, the collection of gut bacteria involved in estrogen metabolism, is a real mechanism. I’ve written about what the research does and doesn’t yet show there, and the honest summary is that the connection is established, but a validated recommendation, take this strain because it shifts hormone metabolism this way, doesn’t exist yet. What follows here is a different, narrower question: of what’s actually been tested in trials, what holds up, and what’s mostly the label doing the talking.
Why the Same Word “Probiotic” Can Mean Totally Different Things
“Probiotic” isn’t one thing. It’s a category that includes hundreds of distinct strains across a handful of genera, and a 2025 systematic review and meta-analysis pooling 16 randomized trials and 2,823 people with IBS found that efficacy is strain-specific, not species-wide. Lacticaseibacillus rhamnosus IDCC 3201 showed a real benefit for constipation-predominant symptoms. Certain Lactiplantibacillus plantarum strains and Bifidobacterium longum CECT 7347 showed benefit specifically for diarrhea-predominant symptoms. Other well-known names in the category, including Lactobacillus casei Shirota, didn’t separate from placebo at all in the pooled data.
That’s the detail almost no front label makes easy to find. Two products can both say “Lactobacillus rhamnosus” and be genuinely different products, because the strain identifier after the species name, the string of letters and numbers most people skip past, is what the trial was actually run on.
None of this research was done specifically in perimenopausal women. It was done in people diagnosed with IBS, which is a different population, though the two groups overlap heavily in the symptoms this site covers: bloating, irregular motility, discomfort without a clean diagnosis. I’m applying IBS-trial evidence to a perimenopausal readership because the symptom overlap is real and no better-matched research exists yet, not because the two are interchangeable.
Does the Pricier One With More Billions Actually Work Better?
Here’s the part that runs against most of the marketing in this category. A 2006 trial in the American Journal of Gastroenterology randomized 362 women with IBS to placebo or one of three doses of Bifidobacterium infantis 35624: one hundred thousand, one hundred million, or ten billion CFU daily. Only the middle dose, one hundred million, beat placebo on symptom relief. The lowest dose didn’t work. The highest dose, ten billion, a number that would look impressive on a label, also didn’t separate from placebo.
Dose-response in probiotics isn’t a straight line where more is simply better, the way it might be for a vitamin. It’s closer to a window, and being outside that window in either direction can mean no effect, even though a capsule with a bigger number sounds like it should work harder.
This is one trial, on one strain, and it hasn’t been replicated at that scale since. I’m not presenting it as settled fact about all probiotics, only as a real, published, adequately powered example of why “more billions” isn’t a reliable proxy for “more effective.”
The spore-forming argument is real, but it’s not the whole picture
Some products market themselves specifically on surviving stomach acid, usually spore-forming strains like Bacillus coagulans. The mechanism behind that claim is genuine: a 2019 in-vitro study modeling digestion found Bacillus coagulans MTCC 5856 spores survived simulated gastric conditions at rates well above what’s typically reported for standard Lactobacillus strains, which are largely broken down by stomach acid before reaching the intestine.
Two things temper that finding. It’s a lab simulation of digestion, not a measurement of what happens inside an actual person. And MTCC 5856 is a strain patented and marketed by the company that also funded much of the published research behind it, which doesn’t make the finding false, but it does mean the source is worth naming rather than treating as neutral.
The human trial data for this same strain is thinner than the mechanism story suggests. A small placebo-controlled trial, 36 people with IBS total, split across groups, tested MTCC 5856 at two billion CFU daily for 90 days and found a real reduction in bloating. Thirty-six people is a small trial to build a purchasing decision on, whatever the direction of the result.
The label may not match what’s in the capsule
Even a well-chosen strain at a well-matched dose only helps if the capsule contains what it claims. A 2025 study out of the UK tested five commercial human probiotic products for viable bacterial content against their label claims. Four of the five fell short of their stated CFU count. One product, a tablet claiming 200 billion CFU per gram, showed no colony growth at all on any test plate, meaning none of the labeled bacteria were alive and viable by the time it was tested.
Five products is a small sample, and I want to be honest that it’s not a statement about the whole industry. It’s a real, recent, peer-reviewed data point showing that “the label says X” and “the capsule contains X” are two different claims, and the gap between them isn’t rare enough to assume it won’t apply to what’s in your cabinet right now.
| What the label emphasizes | What it actually tells you |
|---|---|
| Total CFU count | Almost nothing about effectiveness for a specific symptom pattern |
| Species name alone (“Lactobacillus,” “Bifidobacterium”) | Not enough. Efficacy is tied to the specific strain identifier, not the species |
| “Billions of CFU at time of manufacture” | Not the same claim as CFU at the point you actually swallow it |
| Proprietary blend | Often means individual strain doses aren’t disclosed at all |
| Third-party test seal (NSF, USP, ConsumerLab) | The closest thing to independent confirmation the label contains what it claims |
What this looks like in practice
Not a stack to layer all at once, and not a decision to make purely on CFU count.
Look for the strain identifier, past the species name. A genuine product listing will show something like “Lactobacillus plantarum 299v,” rather than stopping at “Lactobacillus plantarum.” A label that only shows the species is skipping the detail that matters.
Match the strain to your actual pattern, where the trial evidence supports it. Constipation-leaning symptoms and diarrhea-leaning symptoms have shown benefit from different strains in trial data. A single generic multi-strain blend isn’t built around that distinction.
Give one product 4 to 8 weeks before judging it. Most of the trials referenced here ran 8 to 12 weeks. Switching every few days makes it impossible to know if something is working or if you simply haven’t given it enough time.
Third-party testing matters more than the front-of-label number. A verified seal from an independent lab is a stronger signal than any CFU count printed by the manufacturer itself.
Common questions
What’s the best probiotic strain for perimenopause bloating specifically?
No trial has tested probiotic strains in a perimenopausal population specifically. The strongest strain-specific evidence comes from IBS trials, where symptom overlap with perimenopausal bloating is real but not identical.
Is a higher CFU count always a better product?
No. A 2006 trial found that the middle of three tested doses worked while both a much lower and a much higher dose failed to beat placebo, on the same strain. More isn’t automatically better.
Are the “Survives Stomach Acid” Probiotics Actually Better?
The gastric survival mechanism is real in lab simulations, but the human trial evidence for symptom improvement with this strain is limited to one small 36-person study, and it’s a manufacturer-affiliated one at that. Better survival in a lab model hasn’t yet been shown to translate into a clearly larger clinical effect.
How do I know if a probiotic is actually working?
Track a specific symptom, like bloating frequency or stool consistency, for several weeks before and after starting, since global feelings of “better” are hard to trust without something concrete to compare against.
Should I take a probiotic every day, or cycle on and off?
Most of the trial designs referenced here used continuous daily dosing for 8 to 12 weeks, not cycling, so continuous use during any trial period is the better-supported approach if you’re trying to evaluate a specific product.
Does refrigeration actually matter?
It depends on the strain and formulation; some are shelf-stable by design, others lose viability faster at room temperature. The product’s own storage instructions are more reliable here than a general rule, since formulations vary enough that a blanket answer would be misleading.
So Which One Should I Actually Buy?
Because probiotics aren’t one product category with one right choice. Different strains, at different doses, in different symptom patterns, produce different results in the trial data, which is the same reason a single supplement aisle has hundreds of options claiming to do the same thing.
None of this adds up to a single named product worth buying, on purpose. Grading strain and dose evidence is one part of the decision. What I’d actually spend money on, and why, gets graded with the same honesty on its own.
Fortylight is written by Nina Halvorsen, a food scientist, not a physician, dietitian, or licensed health professional. Nothing here is medical advice. Digestive symptoms can signal serious conditions. If you have blood in your stool, unexplained weight loss, persistent vomiting, difficulty swallowing, bleeding after menopause, or symptoms that began after age 50, see a doctor before trying anything on this site.